Management of the extravasation of anti-neoplastic agents

Supportive Care in Cancer

Volumn 23, Issue 5, 2015, Pages 1459-1471

  Boulanger, J ^a   Ducharme, A ^b   Dufour, A ^c   Fortier, S ^d   Almanric, K ^e  

^a Institut National D'excellence en Santé et en Services Sociaux   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c HÔPITAL CHARLES LEMOYNE   (Canada)

^d ROYAL VICTORIA HOSPITAL   (Canada)

^e Hôpital Cité de la Santé et Direction de Santé Publique de Laval   (Canada)

Author keywords

Antidote; Chemotherapy; Extravasation; Management

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; DACARBAZINE; DEXAMETHASONE; DIMETHYL SULFOXIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; HYALURONIDASE; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; MELPHALAN; MITOMYCIN; MITOXANTRONE; NAVELBINE; NELARABINE; OXALIPLATIN; PACLITAXEL; RAZOXANE; SODIUM THIOSULFATE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; HYALURONOGLUCOSAMINIDASE; THIOSULFATE;

CANCER CHEMOTHERAPY; DIFFERENTIAL DIAGNOSIS; EXTRAVASATION; FOLLOW UP; HUMAN; INJECTION SITE; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYMPTOM ASSESSMENT; ADVERSE EFFECTS; CANADA; CATHETERIZATION; CENTRAL VENOUS CATHETERIZATION; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; NEOPLASMS;

ANTINEOPLASTIC AGENTS; CATHETERIZATION, CENTRAL VENOUS; CATHETERIZATION, PERIPHERAL; DEXRAZOXANE; DIMETHYL SULFOXIDE; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; HUMANS; HYALURONOGLUCOSAMINIDASE; NEOPLASMS; QUEBEC; RISK FACTORS; THIOSULFATES;

EID: 84926188009     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-015-2635-7     Document Type: Review

References (62)

1. Infusion Nurses Society (2011) Infusion nursing standards of practice. J Infus Nurs 341(1 Suppl):S1–S110
2. Cox K, Stuart-Harris R, Abdini G, Grygiel J, Raghavan D (1988) The management of cytotoxic-drug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148(4):185–189
3. Schulmeister L (2007) Extravasation management. Semin Oncol Nurs 23(3):184–190. doi:10.1016/j.soncn.2007.05.003
4. Viale PH (2006) Chemotherapy and cutaneous toxicities: implications for oncology nurses. Semin Oncol Nurs 22(3):144–151. doi:10.1016/j.soncn.2006.04.007
5. Bertelli G, Gozza A, Forno GB, Vidili MG, Silvestro S, Venturini M, Del Mastro L, Garrone O, Rosso R, Dini D (1995) Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13(11):2851–2855
6. EONS (2007) Extravasation guidelines, http://www.cancernurse.eu/documents/EONSClinicalGuidelinesSection6-en.pdf#search¼. Accessed October 2013
7. Larson DL (1982) Treatment of tissue extravasation by antitumor agents. Cancer 49(9):1796–1799
8. Schulmeister L (2011) Extravasation management: clinical update. Semin Oncol Nurs 27(1):82–90. doi:10.1016/j.soncn.2010.11.010
9. HYCCN (2013) Guidelines for the management of chemotherapy extravasation in adults. http://www.hyccn.nhs.uk/Downloads/HYCCN%20guidelines%20for%20the%20management%20of%20chemotherapy%20extravasation%20v1.4%202011.pdf. Accessed 17 October 2013
10. Cook DJ, Guyatt GH, Laupacis A, Sackett DL (1992) Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 102(4 Suppl):305S–311S
11. Sauerland C, Engelking C, Wickham R, Corbi D (2006) Vesicant extravasation part I: mechanisms, pathogenesis, and nursing care to reduce risk. Oncol Nurs Forum 33(6):1134–1141. doi:10.1188/06.ONF. 1134-1141
12. Bertelli G (1995) Prevention and management of extravasation of cytotoxic drugs. Drug Saf 12(4):245–255
13. Ener RA, Meglathery SB, Styler M (2004) Extravasation of systemic hemato-oncological therapies. Ann Oncol 15(6):858–862
14. Dorr RT (1990) Antidotes to vesicant chemotherapy extravasations. Blood Rev 4(1):41–60
15. Langer SW, Sehested M, Jensen PB (2000) Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res 6(9):3680–3686
16. Raymond E, Faivre S, Woynarowski JM, Chaney SG (1998) Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 25(2 Suppl 5):4–12
17. Doornaert M, Monstrey S, Roche N (2013) Extravasation injuries: current medical and surgical treatment. Acta Chir Belg 113(1):1–7
18. West of Scotland Cancer Advisory Network Clinical Leads Group (WOSCAN) (2009) Chemotherapy extravasation guideline. WOSCAN, Glasgow
19. GONG (2007) Assessment, prevention and management of extravasation of cytotoxic medications. http://www.gha.net.au/uploadlibrary/393586908extravasation_guidelines0907.pdf. Accessed 11 October 2013. 8 p
20. Goolsby TV, Lombardo FA (2006) Extravasation of chemotherapeutic agents: prevention and treatment. Semin Oncol 33(1):139–143. doi:10.1053/j.seminoncol.2005.11.007
21. Kassner E (2000) Evaluation and treatment of chemotherapy extravasation injuries. J Pediatr Oncol Nurs 17(3):135–148. doi:10.1053/jpon.2000.8063
22. Schrijvers DL (2003) Extravasation: a dreaded complication of chemotherapy. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 14(Suppl 3):iii26–iii30
23. Perez Fidalgo JA, Garcia Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F (2012) Management of chemotherapy extravasation: ESMO–EONS clinical practice guidelines. Eur J Oncol Nurs: Off J Eur Oncol Nurs Soc 16(5):528–534
24. Polovich M, Whitford J, Olsen M (92009) Chemotherapy and Biotherapy Guidelines and Recommendations for Practice (3rd ed.). Oncology Nursing Society
25. De Wit M, Ortner P, Lipp HP, Sehouli J, Untch M, Ruhnke M, Mayer-Steinacker R, Bokemeyer C, Jordan K (2013) Management of cytotoxic extravasation—ASORS expert opinion for diagnosis, prevention and treatment. Onkologie 36(3):127–135. doi:10.1159/000348524
26. Schulmeister L, Pollack CV Jr (2011) Images in emergency medicine. Swollen hand. Anthracycline chemotherapy extravasation. Ann Emerg Med 57(4):417–422. doi:10.1016/j.annemergmed.2010.05.026
27. BCCA (2012) Prevention and management of extravasation of chemotherapy. http://www.bccancer.bc.ca/NR/rdonlyres/B10C0DC3-D799-45E8-8A61-A93F00906737/59243/III_20_ExtravasationManagement_1Jun2013.pdf. Accessed 11 October 2013
28. Spiegel RJ (1981) The acute toxicities of chemotherapy. Cancer Treat Rev 8(3):197–207
29. Yosowitz P, Ekland DA, Shaw RC, Parsons RW (1975) Peripheral intravenous infiltration necrosis. Ann Surg 182(5):553–556
30. Hirsh JD, Conlon PF (1983) Implementing guidelines for managing extravasation of antineoplastics. Am J Hosp Pharm 40(9):1516–1519
31. Ignoffo RJ, Friedman MA (1980) Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7(1):17–27
32. Association des pharmaciens des établissements de santé du Québec (APES) (2003) Recueil d’informations pharmaceutiques en oncologie. Montréal, Qc: APES; 2003. http://guide.opq.org/documents/GuideCompletOncologie%20APES200310pdf.pdf. Accessed 11 November 2013
33. Doellman D, Hadaway L, Bowe-Geddes LA, Franklin M, LeDonne J, Papke-O'Donnell L, Pettit J, Schulmeister L, Stranz M (2009) Infiltration and extravasation: update on prevention and management. J Infus Nurs 32(4):203–211. doi:10.1097/NAN.0b013e3181aac04200129804-200907000-00010
34. Rapid Aid Ltd (2013) http://rapidaid.com/home/products/index.html. Accessed 6 January 2014
35. Bozkurt AK, Uzel B, Akman C, Ozguroglu M, Molinas Mandel N (2003) Intrathoracic extravasation of antineoplastic agents: case report and systematic review. Am J Clin Oncol 26(2):121–123. doi:10.1097/01.COC.0000017088.74592.96
36. Wickham R, Engelking C, Sauerland C, Corbi D (2006) Vesicant extravasation part II: evidence-based management and continuing controversies. Oncol Nurs Forum 33(6):1143–1150. doi:10.1188/06/ONF. 1143-1150
37. Olver IN, Aisner J, Hament A, Buchanan L, Bishop JF, Kaplan RS (1988) A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 6(11):1732–1735
38. Alberts DS, Dorr RT (1991) Case report: topical DMSO for mitomycin-C-induced skin ulceration. Oncol Nurs Forum 18(4):693–695
39. Wiseman LR, Spencer CM (1998) Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs 56(3):385–403
40. Mouridsen HT, Langer SW, Buter J, Eidtmann H, Rosti G, de Wit M, Knoblauch P, Rasmussen A, Dahlstrom K, Jensen PB, Giaccone G (2007) Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol 18(3):546–550. doi:10.1093/annonc/mdl413
41. Fontaine C, Noens L, Pierre P, De Greve J (2012) Savene(R) (dexrazoxane) use in clinical practice. Support Care Cancer 20(5):1109–1112. doi:10.1007/s00520-012-1382-2
42. Langer SW (2010) Extravasation of chemotherapy. Curr Oncol Rep 12(4):242–246. doi:10.1007/s11912-010-0110-7
43. Langer SW, Thougaard AV, Sehested M, Jensen PB (2006) Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. Cancer Chemother Pharmacol 57(1):125–128. doi:10.1007/s00280-005-0022-7
44. Bertelli G, Dini D, Forno GB, Gozza A, Silvestro S, Venturini M, Rosso R, Pronzato P (1994) Hyaluronidase as an antidote to extravasation of Vinca alkaloids: clinical results. J Cancer Res Clin Oncol 120(8):505–506
45. Stanford BL, Hardwicke F (2003) A review of clinical experience with paclitaxel extravasations. Support Care Cancer 11(5):270–277. doi:10.1007/s00520-003-0441-0
46. Dubois A, Fehr M, Bochtler H, Koechli O (1996) Clinical course and management of paclitaxel extravasation. Oncol Rep 3(5):973–974
47. Bertelli G, Cafferata MA, Ardizzoni A, Gozza A, Rosso R, Dini D (1997) Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer 79(11):2266–2269. doi:10.1002/(SICI)1097-0142(19970701)79
48. Kretzschmar A, Pink D, Thuss-Patience P, Dorken B, Reichert P, Eckert R (2003) Extravasations of oxaliplatin. J Clin Oncol 21(21):4068–4069. doi:10.1200/JCO.2003.99.095JCO.2003.99.095
49. Langer SW, Sehested M, Jensen PB (2009) Anthracycline extravasation: a comprehensive review of experimental and clinical treatments. Tumori 95(3):273–282
50. Dorr RT, Alberts DS (1985) Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J Natl Cancer Inst 74(1):113–120
51. Tsavaris NB, Komitsopoulou P, Karagiaouris P, Loukatou P, Tzannou I, Mylonakis N, Kosmidis P (1992) Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. Cancer Chemother Pharmacol 30(4):330–333
52. Boyle DM, Engelking C (1995) Vesicant extravasation: myths and realities. Oncol Nurs Forum 22(1):57–67
53. Heckler FR (1989) Current thoughts on extravasation injuries. Clin Plast Surg 16(3):557–563
54. Loth TS, Eversmann WW Jr (1986) Treatment methods for extravasations of chemotherapeutic agents: a comparative study. J Hand Surg Am 11(3):388–396
55. Rudolph R, Larson DL (1987) Etiology and treatment of chemotherapeutic agent extravasation injuries: a review. J Clin Oncol 5(7):1116–1126
56. Scuderi N, Onesti MG (1994) Antitumor agents: extravasation, management, and surgical treatment. Ann Plast Surg 32(1):39–44
57. Gonzalez T (2013) Chemotherapy extravasations: prevention, identification, management, and documentation. Clin J Oncol Nurs 17(1):61–66. doi:10.1188/13.CJON.61-66PRX1P674584LK1N0
58. ONS (2009) Chemotherapy and biotherapy guidelines and recommendations for practice (3rd ed.). 376 p
59. Atallah E, Salomon, M, Schiffer, C.A. et El-Rayes, B (2006) The role of venography in the evaluation of malfunctioning central venous access ports (CVAPs). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 24 (18S Abstract 18535)
60. Rittenberg CN, Gralla RJ, Rehmeyer TA (1995) Assessing and managing venous irritation associated with vinorelbine tartrate (Navelbine). Oncol Nurs Forum 22(4):707–710
61. Biocodex inc (2011) Monographie Totect. Mai 2011. Accessed 2 August 2013
62. Polovich M., White, J., & Kelleher, L. (Eds.). Chemotherapy and biotherapy guidelines and recommendations for practice (2nd ed.). Pittsburgh, PA: Oncology Nursing Society